Disease-free, overall survival inferior for black women with HR-positive breast cancer
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009. "Black women had a higher risk for disease recurrence and inferior survival compared with women of other races," said Joseph A. Sparano, M.D., professor of medicine and women's health at Albert Einstein Medical College of Medicine and associate chairman of the Department of Oncology at Montefiore Medical Center in Bronx, N.Y.
"The worse outcome was seen only in those with HR-positive, HER-2–negative breast cancer, which is the most common type of breast cancer" he added.
Previous research has shown that black women have worse outcomes in operable breast cancer, likely explained by their higher incidence of more advanced-stage disease, more aggressive triple-negative disease, disparities in medical care, and comorbidities.
"When we controlled for these other factors to the extent possible, black race was still associated with a worse outcome, but only in HR-positive disease — this was a new and surprising finding," said Sparano.
The researchers evaluated survival outcomes in 4,817 women (405 were black) with stage 1 to 3 axillary lymph node-positive or high-risk node-negative breast cancer who had undergone surgery. The women were part of the Eastern Cooperative Oncology Group and Breast Cancer Intergroup trial E1199; they received doxorubicin and taxane-containing chemotherapy plus standard hormonal therapy.
"We found that black patients exhibited similar adherence to the chemotherapy and hormonal therapy, and they didn't do worse if they had other breast cancer subtypes. This indicates that black women with HR-positive breast cancer are more prone to have disease recurrence despite state of the art medical care," said Sparano.
The researchers are planning additional studies to evaluate whether these findings can be attributed to differences in black women's ability to metabolize hormonal therapies.
Source: American Association for Cancer Research
Articles on the same topic
- Novel detection method unmasks circulating breast cancer cellsSat, 12 Dec 2009, 1:24:17 UTC
- Clinical trial advances new approach to re-sensitizing breast cancerFri, 11 Dec 2009, 23:59:12 UTC
- Targeted therapy prolongs life in patients with HER2-positive breast cancerFri, 11 Dec 2009, 18:59:03 UTC
- Anti-estrogens may offer protection against lung cancer mortalityFri, 11 Dec 2009, 16:44:58 UTC
- A new mouse could help understand how some lung cancer cells evade drug treatmentWed, 9 Dec 2009, 5:24:07 UTC
- Decline in breast cancer: Not just because of hormone therapyTue, 8 Dec 2009, 11:08:30 UTC
- Tiny RNA has big impact on lung cancer tumorsMon, 7 Dec 2009, 12:08:11 UTC
Other sources
- Anti-estrogens may offer protection against lung cancer mortalityfrom Science DailyMon, 14 Dec 2009, 4:14:17 UTC
- Clinical trial advances new approach to re-sensitizing breast cancerfrom PhysorgSun, 13 Dec 2009, 18:56:11 UTC
- Clinical trial advances new approach to re-sensitizing breast cancerfrom Science DailySun, 13 Dec 2009, 5:14:07 UTC
- Novel detection method unmasks circulating breast cancer cellsfrom Science BlogSat, 12 Dec 2009, 1:21:13 UTC
- Anti-estrogens may offer protection against lung cancer mortalityfrom Science BlogFri, 11 Dec 2009, 21:56:31 UTC
- Disease-free, overall survival inferior for black women with HR-positive breast cancerfrom Science BlogFri, 11 Dec 2009, 21:56:27 UTC
- Targeted therapy prolongs life in patients with HER2-positive breast cancerfrom Science BlogFri, 11 Dec 2009, 21:56:11 UTC
- Targeted therapy prolongs life in patients with HER2-positive breast cancerfrom PhysorgFri, 11 Dec 2009, 21:28:06 UTC
- Targeted therapy prolongs life in patients with HER2-positive breast cancerfrom Science DailyFri, 11 Dec 2009, 21:21:13 UTC
- Most Oncologists Feel New Genetic Test for Tamoxifen Sensitivity Not Ready for the Clinicfrom PhysorgFri, 11 Dec 2009, 20:14:52 UTC
- Targeted therapy prolongs life in patients with HER2-positive breast cancerfrom Science BlogFri, 11 Dec 2009, 20:07:16 UTC
- Disease-free, overall survival inferior for black women with HR-positive breast cancerfrom Science BlogFri, 11 Dec 2009, 18:56:28 UTC
- Disease-free, overall survival inferior for black women with HR-positive breast cancerfrom PhysorgFri, 11 Dec 2009, 18:21:53 UTC
- Anti-estrogens may offer protection against lung cancer mortalityfrom PhysorgFri, 11 Dec 2009, 17:35:25 UTC
- Anti-estrogens may offer protection against lung cancer mortalityfrom Science BlogFri, 11 Dec 2009, 17:21:25 UTC
- Decline of hormone therapy decreases breast cancer cases, analysis findsfrom PhysorgWed, 9 Dec 2009, 23:14:17 UTC
- New mouse could help understand how some lung cancer cells evade drug treatmentfrom Science DailyWed, 9 Dec 2009, 15:45:13 UTC
- A new mouse could help understand how some lung cancer cells evade drug treatmentfrom PhysorgWed, 9 Dec 2009, 10:49:14 UTC
- A new mouse could help understand how some lung cancer cells evade drug treatmentfrom Science BlogWed, 9 Dec 2009, 6:07:21 UTC
- Decline in breast cancer: Not just because of hormone therapyfrom PhysorgTue, 8 Dec 2009, 11:07:07 UTC
- Tiny RNA has big impact on lung cancer tumorsfrom Biology News NetMon, 7 Dec 2009, 23:56:37 UTC
- Tiny RNA has big impact on lung cancer tumorsfrom Science DailyMon, 7 Dec 2009, 17:14:30 UTC
- Tiny RNA has big impact on lung cancer tumorsfrom Science BlogMon, 7 Dec 2009, 12:49:16 UTC
- Tiny RNA has big impact on lung cancer tumorsfrom PhysorgMon, 7 Dec 2009, 12:07:06 UTC